Diaceutics PLC - 75% ARR Growth Drives Revenue & Profit Visibility
Diaceutics PLC H1 2026 Trading Update
Strong ARR growth of 75% drives H2 2026 revenue and profit visibility
Revenue grows 22% on a constant currency basis to
Annual Recurring Revenue ('ARR') up 75% to
Order book of
Gross margin expected to be 87% and Adjusted EBITDA* expected to be
Continued growth in number of customer therapeutic brands to 99 as the Company expands into the Precision for All market opportunity
Strong balance sheet with no debt and cash of
Ryan Keeling, Diaceutics' Chief Executive Officer, commented: "I am more confident than ever in Diaceutics and the long-term value we can create for shareholders. H1 revenue grew 22% at constant currency to
ARR reached
We are demonstrating good operating leverage. Revenue is growing faster than the underlying cost base, gross margin increased to 87%, and we expect to report H1 Adjusted EBITDA of
Precision for All is expanding our addressable market, while PMx is creating deeper enterprise relationships and longer-duration recurring revenue. Our proprietary diagnostic data, technology and application of AI provide a differentiated platform from which to capture this opportunity.
We enter H2 with record forward visibility. Our
We are growing revenues, increasing recurring revenue, retaining and expanding customers, and building our order book to record levels. That combination gives me strong confidence in delivery for FY 2026 and in our continued ability to create significant long-term shareholder value."
Trading Update to
Revenue for H1 2026 is
The visibility and sustainability of revenues continued to improve during H1 2026 as the business expands its share of the Precision for All market opportunity through fostering its enterprise-wide customer relationships with global pharma and biotech.
Annual Recurring Revenue ('ARR') increased 75% to
Diaceutics continues to work with 18 of the top 20 global pharma companies, and over a TTM period has supported a total of 54 customers across 99 therapeutic brands (TTM ended
The contracted order book continued to expand and was
Adjusted EBITDA* is expected to be
Cash at
Outlook
|
· Entering H2 with strong commercial momentum, increasing market opportunity, improved customer retention and enhanced revenue visibility |
|
· Global pharma and biotech customers continue to embrace Precision for All to improve patient access, capture lost revenue and optimize their commercial outcomes · AI is being embedded across the DXRX platform and operating model to enhance customer insights, improve productivity and strengthen the scalability and defensibility of Diaceutics' proprietary data assets · Management's priorities remain disciplined organic growth, recurring revenue expansion, cash conversion and cost control · The success of the Company's strategy and strength of its recurring revenues, order book and pipeline provide the Board confidence that the Company targets for 2026 are on track |
|
The Group expects to announce its interim results in late
|
All numbers stated are unaudited.
*Adjusted EBITDA is earnings before interest, tax, depreciation, amortisation and exceptional items.
** Median analyst consensus estimates for FY 2026 revenue are
Enquiries:
|
Diaceutics PLC |
|
|
|
Tel: +44 (0)28 9040 6500 investorrelations@diaceutics.com
|
|
|
|
|
Canaccord Genuity Limited (Nomad & Broker) |
Tel: +44 (0)20 7523 8000 |
|
|
|
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.
Prior to publication the information communicated in this announcement was deemed by the Company to constitute inside information for the purposes of article 7 of the Market Abuse Regulations (EU) No 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations No 2019/310 ('MAR'). With the publication of this announcement, this information is now considered to be in the public domain. The person responsible for making this announcement on behalf of the Company is
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE